Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16922206 | 0.90 | — | — | |
| SCHEMBL15461483 | 0.78 | PDE4A (0.46) | PDE4AGAA | |
| SCHEMBL10577686 | 0.76 | MEN1 (0.38) | MEN1POLBKMT2APDE4A | |
| SCHEMBL5228365 | 0.75 | MEN1 (0.48) | MEN1POLBKMT2APDE4A | |
| SCHEMBL15461456 | 0.75 | PDE4A (0.42) | PDE4AGAA | |
| SCHEMBL13684412 | 0.70 | MEN1 (0.57) | MEN1POLBKMT2APDE4A | |
| SCHEMBL18500611 | 0.70 | MEN1 (0.44) | MEN1POLBKMT2APDE4A | |
| SCHEMBL12869537 | 0.70 | PDE4A (0.38) | PDE4AGAA | |
| SCHEMBL3330295 | 0.70 | MEN1 (0.44) | MEN1POLBKMT2APDE4A | |
| SCHEMBL5838244 | 0.68 | MEN1 (0.42) | MEN1POLBKMT2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103172589-A | Thiazolyl-dihydroquinazolines | BOEHRINGER INGELHEIM INT | 2013-06-26 | — | — | CN | disclosed |
| CN-101460505-B | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INT | 2013-03-20 | — | — | CN | disclosed |
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| CN-101460505-A | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INT (DE) | 2009-06-17 | — | — | CN | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | MEN1 3210/4885POLB 3674/4885KMT2A 2603/4885 |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | QDPR, NQO2, DHPS | MEN1 362/4885POLB 3803/4885KMT2A 3009/4885 |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | MEN1 729/4885POLB 4064/4885KMT2A 3930/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | MEN1 2630/4885POLB 9/4885KMT2A 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.